He says that phase II clinical trials will begin as quickly as possible by mid-2008 to gauge the effectiveness of rifapentine as a key component to daily, anti-TB drug regimens.

• 他说，二期临床试验将开始尽快由2008年年中，以评估成效，利福喷丁作为一个重要组成部分，每天的抗结核药物方案。